OncoMatch/Clinical Trials/NCT07489534
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Is NCT07489534 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies PD-1Ab21-BCMA CAR-T cell immunotherapy for multiple myeloma.
Treatment: PD-1Ab21-BCMA CAR-T cell immunotherapy — The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal dysfunction.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: clinical first-line treatment
received ≥ 2 courses of clinical first-line treatment, evaluated efficacy above PR
Lab requirements
Blood counts
WBC≥1×10^9/L, LY≥0.3×10^9/L, PT:INR<1.7 or PT prolonged by<4s compared to normal value
Kidney function
Diagnosed with multiple myeloma accompanied by renal dysfunction
Liver function
ALT and AST ≤ 2.5 ULN; Serum total bilirubin ≤ 2.0mg/dL (34.2 μmol/L)
WBC≥1×10^9/L，LY≥0.3×10^9/L，ALT and AST ≤ 2.5 ULN; Serum total bilirubin ≤ 2.0mg/dL (34.2 μmol/L); PT:INR<1.7 or PT prolonged by<4s compared to normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07489534 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received clinical first-line treatment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages